Neoleukin Therapeutics Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Neoleukin Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Neoleukin Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Neoleukin Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 143.3 M | |
| Total Cashflows From Investing Activities | -59.1 M |
Neoleukin |
Neoleukin Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Neoleukin Therapeutics on October 6, 2025 and sell it today you would earn a total of 100.00 from holding Neoleukin Therapeutics or generate -100.0% return on investment over 90 days. Neoleukin Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Neoleukin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neoleukin Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neoleukin Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neoleukin Therapeutics, and traders can use it to determine the average amount a Neoleukin Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NLTX |
Based on monthly moving average Neoleukin Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neoleukin Therapeutics by adding Neoleukin Therapeutics to a well-diversified portfolio.
Neoleukin Therapeutics Fundamentals Growth
Neoleukin Stock prices reflect investors' perceptions of the future prospects and financial health of Neoleukin Therapeutics, and Neoleukin Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neoleukin Stock performance.
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | (35.02 M) | |||
| Shares Outstanding | 2.35 M | |||
| Price To Earning | (4.60) X | |||
| Price To Book | 0.44 X | |||
| EBITDA | (56.48 M) | |||
| Cash And Equivalents | 116.46 M | |||
| Cash Per Share | 2.73 X | |||
| Total Debt | 12.07 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 34.18 X | |||
| Cash Flow From Operations | (45.61 M) | |||
| Earnings Per Share | (12.28) X | |||
| Total Asset | 115.95 M | |||
| Retained Earnings | (451.06 M) | |||
| Current Asset | 289 K | |||
| Current Liabilities | 1.02 M | |||
Things to note about Neoleukin Therapeutics performance evaluation
Checking the ongoing alerts about Neoleukin Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neoleukin Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neoleukin Therapeutics is not yet fully synchronised with the market data | |
| Neoleukin Therapeutics has some characteristics of a very speculative penny stock | |
| Neoleukin Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (57.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neoleukin Therapeutics currently holds about 116.46 M in cash with (45.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Neoleukin Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neoleukin Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Neoleukin Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neoleukin Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neoleukin Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neoleukin Therapeutics' stock. These opinions can provide insight into Neoleukin Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |